• / Free eNewsletters & Magazine
  • / My Account
Home>Global CAR-T r/r CLL Market Forecast to 2030 - Research and Markets

Global CAR-T r/r CLL Market Forecast to 2030 - Research and Markets

Global CAR-T r/r CLL Market Forecast to 2030 - Research and Markets

10/05/2017

Global CAR-T r/r CLL Market Forecast to 2030 - Research and Markets

The "CAR-T r/r CLL Global Market Forecast" report has been added to Research and Markets' offering.

Novel immune-therapeutic approaches in development for CLL include monoclonal antibodies, bi-specific antibodies, anti-PD1/PDL-1 checkpoint inhibitors, and the CAR-T cell therapies including JCAR014/JCAR017 (Juno Therapeutics), KTE-C19 (Kite Pharma), and CTL019 (tisagenlecluecel-T)(Novartis Pharmaceuticals). These potential CAR-T therapies or their next generations e.g. armoured' CARs and humanized versions are in development.

This product consists of a detailed Executive presentation (

130 slides, .pdf) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies in r/r CLL across 9 major Western markets to 2030.

A patient based flow methodology has been devised where possible intervention scenarios for CAR-T introduction are visualised so that the optimum product positioning can be assessed. In addition, an up-to-date review of CLL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T CLL competitive landscape. Pricing, cost effectiveness, manufacturing and logistical considerations are also discussed. All assumptions are clearly provided.

Key Topics Covered:

1. Executive Summary

©2017 Morningstar Advisor. All right reserved.